Gene Expression Panels for Prostate Cancer Outcome Prediction

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current methods for predicting prostate cancer progression and mortality in men with rising PSA levels after definitive therapy are inadequate, as not all patients with PSA recurrence will develop systemic disease or die from prostate cancer, leading to unnecessary treatments and uncertainty regarding the need for additional therapy.

Innovation Solution

A method involving the determination of an expression profile score based on the mRNA levels of RAD21, CDKN3, CCNB1, SEC14L1, BUB1, ALAS1, KIAA0196, TAF2, SFRP4, STIP1, CTHRC1, SLC44A1, IGFBP3, EDG7, FAM49B, C8orf53, and CDK10 nucleic acids, combined with clinical variables, to predict the likelihood of systemic disease development and mortality from prostate cancer.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If PSA recurrence monitoring is used after definitive therapy, then early detection of potential systemic disease is improved, but unnecessary treatment and patient anxiety increase due to inability to distinguish indolent from aggressive disease

Engineering Contradiction:

Improveprediction accuracy of systemic disease developmentVSAvoidcomplexity of prediction method

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent segments the homogeneous group of PSA-recurrence patients into distinct subgroups based on gene expression profiles. By analyzing specific genes (e.g., BUB1, CCNB1, CDK10, CDKN3, EDG7, IGFBP3, RAD21, SFRP4, STIP1, TAF2) that regulate cell cycle, apoptosis, and metastasis, the method divides patients into those likely to develop systemic disease versus those with indolent disease, enabling personalized treatment decisions

Inventive Principle:

Principle #1Segmentation

Solution Approach 2:

The patent introduces gene expression profiling as an intermediary biomarker between PSA recurrence detection and treatment decision-making. This molecular intermediary provides mechanistic insight into tumor biology, allowing clinicians to predict systemic disease development without immediately subjecting all patients to aggressive therapy

Inventive Principle:

Principle #24Intermediary (Mediator)

2Reliability

If early androgen ablation is administered to all patients with PSA recurrence, then potential systemic disease progression is reduced, but treatment-related side effects and quality of life deterioration increase for patients with indolent disease

Engineering Contradiction:

Improveprediction accuracy of mortality riskVSAvoidtreatment side effects and quality of life impact

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent applies local quality by tailoring treatment intensity to the specific molecular characteristics of each patient's tumor. Patients with gene expression profiles indicating high risk of systemic disease receive aggressive therapy, while those with low-risk profiles are managed with surveillance alone, avoiding unnecessary exposure to androgen deprivation therapy side effects

Inventive Principle:

Principle #3Local quality

Solution Approach 2:

The patent changes the decision-making parameter from uniform PSA threshold-based treatment to gene expression-based risk stratification. By measuring mRNA levels of specific genes and calculating risk scores, the system transforms the treatment indication criterion, enabling differentiation between patients who benefit from therapy versus those who do not

Inventive Principle:

Principle #35Parameter changes

3Ease of operation

If observation alone is used for patients with PSA recurrence, then treatment-related side effects are avoided, but delayed intervention allows aggressive disease to progress

Engineering Contradiction:

Improvesimplicity of treatment decisionVSAvoidaccuracy of distinguishing indolent from aggressive disease

Core Design Contradiction:

Ease of operationVSReliability

Solution Approach 1:

The patent replaces the mechanical/clinical observation approach with a molecular biology-based diagnostic system. Instead of relying on clinical follow-up and PSA monitoring alone, the method uses gene expression analysis to objectively assess tumor aggressiveness, substituting molecular mechanisms for clinical judgment

Inventive Principle:

Principle #28Mechanics substitution (Replace mechanical system)

4Measurement precision

If comprehensive gene expression profiling is performed, then prediction accuracy of systemic disease and mortality is improved, but test complexity and cost increase

Engineering Contradiction:

Improveprecision of systemic disease predictionVSAvoidcomplexity of gene expression analysis

Core Design Contradiction:

Measurement precisionVSDevice complexity

Solution Approach 1:

The patent extracts and focuses on a specific subset of genes most relevant to prostate cancer progression and systemic disease development. Rather than analyzing the entire transcriptome, the method identifies and measures expression levels of key genes involved in cell cycle regulation (BUB1, CCNB1, CDK10, CDKN3), apoptosis (IGFBP3), and metastasis (EDG7, RAD21, SFRP4, STIP1, TAF2), simplifying the analytical complexity while maintaining predictive power

Inventive Principle:

Principle #2Taking out (Extraction)

Data Source

PatentUS10407731B2Biomarker panels for predicting prostate cancer outcomes

Publication Date: 2019.09.10 MAYO FOUNDATION FOR MEDICAL EDUCATION & RESEARCH

AI summary

This document provides methods and materials related to assessing male mammals (e.g., humans) with prostate cancer. For example, methods and materials for predicting (1) which patients, at the time of PSA reoccurrence, will later develop systemic disease, (2) which patients, at the time of retropubic radial prostatectomy, will later develop systemic disease, and (3) which patients, at the time of systemic disease, will later die from prostate cancer are provided.